152 related articles for article (PubMed ID: 11319229)
21. The role of alpha 2-antiplasmin in the inhibition of clot lysis in newborns and adults.
Ries M; Klinge J; Rauch R; Keuper H; Harms D
Biol Neonate; 1996; 69(5):298-306. PubMed ID: 8790908
[TBL] [Abstract][Full Text] [Related]
22. Photoaffinity labeling of functionally different lysine-binding sites in human plasminogen and plasmin.
Ryan TJ; Keegan MC
Biochim Biophys Acta; 1985 Aug; 830(2):187-94. PubMed ID: 3160389
[TBL] [Abstract][Full Text] [Related]
23. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen assay by means of the lysis time method.
Berg W; Korsan-Bengtsen K; Ygge J
Thromb Diath Haemorrh; 1965 Sep; 14(1-2):127-44. PubMed ID: 16955971
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of plasmin generation by S100A10.
Miller VA; Madureira PA; Kamaludin AA; Komar J; Sharma V; Sahni G; Thelwell C; Longstaff C; Waisman DM
Thromb Haemost; 2017 Jun; 117(6):1058-1071. PubMed ID: 28382372
[TBL] [Abstract][Full Text] [Related]
26. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11.
He KL; Deora AB; Xiong H; Ling Q; Weksler BB; Niesvizky R; Hajjar KA
J Biol Chem; 2008 Jul; 283(28):19192-200. PubMed ID: 18434302
[TBL] [Abstract][Full Text] [Related]
27. Clot-embedded natural surfactant: kinetics of fibrinolysis and surface activity.
Günther A; Kalinowski M; Elssner A; Seeger W
Am J Physiol; 1994 Nov; 267(5 Pt 1):L618-24. PubMed ID: 7977772
[TBL] [Abstract][Full Text] [Related]
28. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
[TBL] [Abstract][Full Text] [Related]
29. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
Urano S; Metzger AR; Castellino FJ
Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
[TBL] [Abstract][Full Text] [Related]
30. tPA receptors and the fibrinolytic response in multiple sclerosis lesions.
Gveric D; Herrera BM; Cuzner ML
Am J Pathol; 2005 Apr; 166(4):1143-51. PubMed ID: 15793294
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the heparin binding properties of annexin II tetramer.
Kassam G; Manro A; Braat CE; Louie P; Fitzpatrick SL; Waisman DM
J Biol Chem; 1997 Jun; 272(24):15093-100. PubMed ID: 9182528
[TBL] [Abstract][Full Text] [Related]
32. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
[TBL] [Abstract][Full Text] [Related]
33. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
Farrehi PM; Zhu Y; Fay WP
J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
[TBL] [Abstract][Full Text] [Related]
34. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
[TBL] [Abstract][Full Text] [Related]
35. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
[TBL] [Abstract][Full Text] [Related]
36. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
Zhitkova IuV; Aĭsina RB; Varfolomeev SD
Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
[TBL] [Abstract][Full Text] [Related]
37. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo.
Ling Q; Jacovina AT; Deora A; Febbraio M; Simantov R; Silverstein RL; Hempstead B; Mark WH; Hajjar KA
J Clin Invest; 2004 Jan; 113(1):38-48. PubMed ID: 14702107
[TBL] [Abstract][Full Text] [Related]
38. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
39. Fucoidan-dependent conformational changes in annexin II tetramer.
Fitzpatrick SL; Kassam G; Manro A; Braat CE; Louie P; Waisman DM
Biochemistry; 2000 Mar; 39(9):2140-8. PubMed ID: 10694379
[TBL] [Abstract][Full Text] [Related]
40. Regulation of annexin A2 by reversible glutathionylation.
Caplan JF; Filipenko NR; Fitzpatrick SL; Waisman DM
J Biol Chem; 2004 Feb; 279(9):7740-50. PubMed ID: 14668336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
